Viremia is a term that describes the presence of viruses in the blood. Viruses are microscopic organisms that survive and multiply inside living hosts, such as animals and humans. Minor cases of ...

Virologic failure, or the inability to maintain or achieve viral suppression below detectable limits (<50 copies/mL), occurs in some patients with human immunodeficiency virus (HIV)-1 infection, ...

VIREMIA during the course of infections with ECHO viruses has been reported in only a few cases. Neva and Zuffante 1 demonstrated virus in 1 of 10 blood specimens collected two to five days after ...

Overall, 17 of the 49 patients (35%) had viremia at some time. Ten of 26 patients in whom treatment was initiated had viremia; 4 were seronegative (antibody titer, <2560) and 6 were seropositive ...

Though scientists studied only COVID patients, Bain said the findings could benefit people sickened by other respiratory ...

Long-acting antiretroviral therapy (LA-ART) maintained high viral suppression for 48 weeks in patients with HIV regardless of initial viremia. Researchers examined viral suppression for 48 weeks ...

Please provide your email address to receive an email when new articles are posted on . Patients with HIV who have persistent, low-level viremia are at increased risk for virologic failure, according ...

Human immunodeficiency virus (HIV) works by entering specific immune cells and replicating inside them. People with HIV are treated with antiretroviral therapy (ART), which prevents viral replication, ...

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Understanding how the virus affects the body is crucial to ...

Recent studies on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have reported an increased incidence of stillbirth in pregnant people with the coronavirus disease 2019 ...

All patients received ganciclovir 5 mg/kg i.v. b.i.d. from admission until day –2 and acyclovir 10 mg/kg i.v. q 8 h or 800 mg p.o. b.i.d. or t.i.d. from day −1 until day 180 post-transplantation.